Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Novartis last week asked the FDA not to approve any generic copies of its heart failure drug Entresto before its exclusivity period ends in February 2024, citing labeling concerns. The agency denied a similar request from the drugmaker in April. For the treatment of heart failure, Entresto holds covered or better status for virtually all covered lives (99%) under the pharmacy benefit. 66.3% of insured lives have preferred access to Entresto without utilization management restrictions. The drug will likely face heavy competition, with at least 18 generic versions in development.

SOURCE: MMIT Analytics, as of 9/19/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today